{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:24Z","timestamp":1789394544825,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00805-w","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:56:08Z","timestamp":1787943368000},"page":"899-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"kct0007239","registry":"10.18810\/cris"}],"author":[{"given":"Oh Chan","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Un Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Joon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-7355","authenticated-orcid":false,"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"1","key":"805_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter JJ, van Mens LJ, van der Heijde D, Landew\u00e9 R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18(1):196.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"805_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A. Axial spondyloarthritis: a review. JAMA. 2025;333(5):408\u201320.","journal-title":"JAMA"},{"issue":"7","key":"805_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","volume":"67","author":"N Zeboulon","year":"2008","unstructured":"Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"805_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103638","volume":"23","author":"F Proft","year":"2024","unstructured":"Proft F, Duran TI, Ghoreschi K, Pleyer U, Siegmund B, Poddubnyy D. Treatment strategies for spondyloarthritis: implementation of precision medicine\u2014or \u201cone size fits all\u201d concept? Autoimmun Rev. 2024;23(10):103638.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"805_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4078\/jrd.2024.0029","volume":"31","author":"AR Choi","year":"2024","unstructured":"Choi AR, Park KJ, Kang JH, Lee YJ, Jang HH, Kim MJ, et al. The effectiveness of tumor necrosis factor-\u03b1 blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS health index. J Rheum Dis. 2024;31(3):171\u20137.","journal-title":"J Rheum Dis"},{"issue":"9","key":"805_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3899\/jrheum.131289","volume":"41","author":"JC van Denderen","year":"2014","unstructured":"van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014;41(9):1843\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"805_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001161","volume":"6","author":"I van der Horst-Bruinsma","year":"2020","unstructured":"van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1):e001161.","journal-title":"RMD Open"},{"issue":"2","key":"805_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3899\/jrheum.180312","volume":"46","author":"RE van Bentum","year":"2019","unstructured":"van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst C, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab\u2014the GO-EASY study. J Rheumatol. 2019;46(2):153\u20139.","journal-title":"J Rheumatol"},{"issue":"8","key":"805_CR9","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447\u201351.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"805_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02549-0","volume":"23","author":"D Roche","year":"2021","unstructured":"Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther. 2021;23(1):192.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"805_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/art.42788","volume":"76","author":"K Bechman","year":"2024","unstructured":"Bechman K, Yang Z, Adas M, Nagra D, Su A, Russell MD, et al. Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: a systematic review and network meta-analysis. Arthritis Rheumatol. 2024;76(5):704\u201314.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"805_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/rheumatology\/keae003","volume":"64","author":"OC Kwon","year":"2025","unstructured":"Kwon OC, Lee HS, Yang J, Park MC. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis. Rheumatology (Oxford). 2025;64(2):588\u201396.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"805_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"805_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2022","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"805_CR15","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","volume":"30","author":"D Wendling","year":"2014","unstructured":"Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"805_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","volume":"76","author":"E Lie","year":"2017","unstructured":"Lie E, Lindstr\u00f6m U, Zverkova-Sandstr\u00f6m T, Olsen IC, Forsblad-d\u2019Elia H, Askling J, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"805_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","volume":"80","author":"U Lindstr\u00f6m","year":"2021","unstructured":"Lindstr\u00f6m U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d\u2019Elia H, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"805_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030631","volume":"11","author":"SM Ahn","year":"2022","unstructured":"Ahn SM, Kim M, Kim YJ, Lee Y, Kim YG. Risk of acute anterior uveitis in ankylosing spondylitis according to the type of tumor necrosis factor-alpha inhibitor and history of uveitis: a nationwide population-based study. J Clin Med. 2022;11(3):631.","journal-title":"J Clin Med"},{"issue":"1","key":"805_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5233","volume":"10","author":"S Vijayan","year":"2022","unstructured":"Vijayan S, Hwangbo K, Barkham N. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: a case series. Clin Case Rep. 2022;10(1):e05233.","journal-title":"Clin Case Rep."},{"issue":"4","key":"805_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"805_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.31138\/mjr.310725.ect","volume":"37","author":"D Deligeorgakis","year":"2026","unstructured":"Deligeorgakis D, Skouvaklidou E, Skepastianos V, Papadimitriou E, Boutel M, Dimitriadou V, et al. Current and emerging therapies for uveitis in axial spondyloarthritis: a scoping review. Mediterr J Rheumatol. 2026;37(Suppl 1):46\u201357.","journal-title":"Mediterr J Rheumatol"},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"issue":"6","key":"805_CR23","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522\u201330.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"805_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","volume":"38","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407\u201315.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"805_CR25","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"805_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","volume":"30","author":"K Kunimi","year":"2022","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-\u03b1 therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2022;30(1):223\u201330.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"805_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/jop.2020.0081","volume":"37","author":"G Ucan Gunduz","year":"2021","unstructured":"Ucan Gunduz G, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: infliximab versus adalimumab. J Ocul Pharmacol Ther. 2021;37(4):236\u201340.","journal-title":"J Ocul Pharmacol Ther"},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","volume":"238","author":"G Maalouf","year":"2022","unstructured":"Maalouf G, Andrillon A, Leclercq M, S\u00e8ve P, Bielefeld P, Gueudry J, et al. Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients. Am J Ophthalmol. 2022;238:173\u201380.","journal-title":"Am J Ophthalmol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00805-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:02:22Z","timestamp":1789390942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00805-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00805-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"11 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y-G Kim has no ownership of Celltrion stocks. Y-G Kim has received honoraria totaling 1000 US dollars for participation in two advisory meetings related to pharmaceutical products from Celltrion. Y-G Kim declares no other conflicts of interest. All other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: Y-GK. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: OCK. Critical revision of the manuscript for important intellectual content: YGK. Statistical analysis: all authors. Administrative, technical, or material support: all authors. Supervision: Y-GK. All authors have read and agreed to the final version of the manuscript.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards (IRBs) of\u00a0all four participating centers: Asan Medical Center in Seoul, South Korea (IRB No: 2022-0492); Gangnam Severance Hospital in Seoul, South Korea (IRB No: 3-2022-0208); Seoul National University Hospital in Seoul, South Korea (IRB No: H-2207-176-1345); and Hanyang University Hospital in Seoul, South Korea (IRB No: HYUH 2022-03-046).","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underlying this study will be made available by the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}